Mass spectrometric approaches to assess the biodistribution and fate of cationic surfactants used as drug delivery nanoparticles

在制药行业中，增长最快的领域是药物递送，目前包括基因递送在内的总价值超过800亿美元。Glybera®基因疗法最近在欧盟首次获得批准，用于治疗遗传性脂质疾病。事实上，有5000种遗传疾病无法治愈。因此，已经进行了2000多项临床试验（即人体试验），评估各种基因治疗策略也就不足为奇了。

In the pharmaceutical industry, the fastest growing area is drug delivery, accounting currently for more than $80 billion of total value, including gene delivery. The latter has gained momentum with the recent first approval in the European Union of the gene therapy, Glybera® for the treatment of genetic lipid disorders. In fact, there are 5000 genetic diseases that do not have a cure. Therefore, it is not surprising that over 2000 clinical trials (i.e. human testing) have been conducted, evaluating various gene therapy strategies.